Lettmann Jason 4

What Happened Jason Lettmann, CEO of ALX Oncology (ALXO), sold 12,311 shares on 2026-03-19 at $2.17 per share, for proceeds of $26,715. The filing reports this sale (code "S") and the seller notes the shares were sold to satisfy tax obligations arising from the vesting of performance-based restricted stock units (RSUs).

Key Details

• Transaction date: 2026-03-19; Price: $2.17/share; Total proceeds: $26,715.
• Transaction type: Sale (reported as open-market or private sale, code "S").
• Purpose: Per footnote F1, shares were sold to satisfy tax withholding on vested performance-based RSUs.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Filing and timeliness: Form 4 filed on 2026-03-23 (report period 2026-03-19); filing appears timely (within standard 2-business-day window).

Context Tax-withholding sales tied to RSU vesting are common and typically routine — they are executed to cover tax obligations rather than as a directional investment bet. Sales like this generally provide limited information about an insider’s private view of the company’s prospects.